safety antigenicity inactivated influenza virus vaccine child trial monovalent bivalent anew jersey76 hswn1 avictoria75 virus vaccine washington dc safety antigenicity monovalent bivalent anew jerseynj76 hssn1 avictoria75 inactivated influenza virus vaccine studied 125 child aged three 18 year recruitment family knew study team professionally involved andor close continuing care likely volunteer study unfamiliar team institution antibody response systemic reaction occurred often administration inactivated wholevirus vaccine splitvirus vaccine significant titer greater equal 140 hemagglutinationinhibiting antibody anj76 virus occurred 95 normal child three 18 year age received two dos vaccine whole split however insufficient number child achieved reasonable antibody titer greater equal 140 one dose vaccine ct 1 vasilyeva ri zh mikrobio epidemio immunobi 1982 96 982